P21
aka P021
Mechanism
P21 (also P021) is a small peptidergic compound — the tetrapeptide core Asp-Gly-Gly-Leu with an N-terminal acetyl and a C-terminal adamantylated glycine amide (Ac-DGGL(A)G-NH2) — derived from an active region (residues ~148–151) of human ciliary neurotrophic factor (CNTF). It was designed and characterized in the Khalid Iqbal laboratory at the New York State Institute for Basic Research in Developmental Disabilities (NYS IBR). It is an experimental, preclinical compound — NOT FDA-approved and NOT tested in humans in published trials. Distinct from the cyclin-dependent kinase inhibitor protein p21/CDKN1A/WAF1 (a completely different gene product; the two share only the name).
Identification
| CAS number | 1246751-68-7 |
|---|---|
| Molecular formula | C27H42N6O8 |
| Sequence | DGGL |
| Typical dose | 500–750 mcg/day intranasal (research use); 250–1000 mcg/day range reported |
| Half-life | >6 hours (rodent; estimated, based on parent Peptide 6 and adamantane-modified stability) |
Vendors selling P21
| Vendor | Size | Price | Listed purity | Trust |
|---|---|---|---|---|
| Skye Peptides | 10 mg | $79.00 | — | 90 |
| Verified Peptides | 10 mg | $119.00 | — | 86 |
| Simple Peptide | 10 mg | $198.00 | — | 85 |
| Peptidegurus | 5 mg | — | — | 84 |
| Core Peptides | 5 mg | $116.00 | — | — |
| Genetic Peptide | 5 mg | $120.00 | — | — |
| Paramount Peptides | 10 mg | $150.00 | — | — |
Research
Introduction CDKN1A (encoding p21) is a canonical regulator of cell cycle arrest and genomic stability. However, its functional spectrum within the tumor microenvironment (TME), especially at single-cell resolution, remains insufficiently defined.
source →Background Unexplained miscarriage (UM) highly occurs and largely limits human reproduction. Cellular senescence is a ubiquitous process that is associated with many human diseases.
source →The CRISPR/Cas9 method facilitates targeted disruption of gene sequences, providing a reliable means to analyze gene-dependent regulatory pathways. This study aims to investigate melanogenesis in p21-knockout B16F1 cells generated by the CRISPR/Cas9 system.
source →The cell cycle orchestrates the events that lead to cell replication and division. AMBRA1 interacts with the E3 ubiquitin ligase CRL4DDB1 complex to regulate the stability of D-type cyclins, key regulators of the G1-S phase transition. However, whether AMBRA1 has a role in the S phase remains to be elucidated.
source →Cellular senescence plays key roles in tissue repair, tumour suppression and ageing. Here we identify a rapid, transcription‑independent senescence response in skin following injury. Within minutes to hours after wounding, skin cells at the edge of injury display hallmark features of senescence.
source →Osteoarthritis (OA) is a disease characterized by progressive cartilage degeneration. P21, as a cell cycle regulator, participates in maintaining cartilage homeostasis.
source →p21 (Cip1/Waf1/Sdi1) , a widely studied member of the CKI (CDK inhibitor) family, has been designated a negative regulator of cell cycle progression.
source →Skeletal muscle differentiation relies on transient DNA strand breaks (DSBs), yet excessive DNA damage remains harmful to myogenic progression.
source →Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality worldwide, with limited therapeutic efficacy and severe side effects associated with conventional chemotherapy, creating an urgent need for safe and effective natural anti-tumor agents.
source →Background and aim The incidence of inflammatory bowel disease among coal miners is globally higher than that in the general population; however, the underlying pathogenic mechanisms remain unclear.
source →Emerging evidence has established that renal tubular epithelial cell (TEC) senescence is an essential driver of renal fibrosis, while the activation of p53/p21 pathway plays a key role in initiating TEC senescence.
source →It is of particular interest to find out whether it is possible to use the novel radiotracer \[18F\]FPyGal to be tested to detect areas after standard tumor therapy that contain resistant (therapy-resistant) tumor cells.
source →This study is intended to demonstrate the superiority of colorectal polyp detection using computer-assisted colonoscopy compared to conventional colonoscopy.
source →The aim of the study is to investigate the antigen-unspecific effect of a 3 months supplementation with a food for special medical purposes (FSMP) in form of a lozenge containing beta-lactoglobulin (BLG), iron, retinoic acid, zinc and polyphenols (holo-BLG) in patients with allergic rhinoconjunctivitis caused by cat (h…
source →This phase II trial studies the effect of atorvastatin in treating patients with ulcerative colitis who have a dominant-negative missense P53 mutation and are at risk of developing large intestinal cancer. Patients with ulcerative colitis are known to have an increased risk of developing large intestinal cancer.
source →The study population will be 50 women or men diagnosed with urothelial cancer candidates to undergo cystectomy as part of their antitumor treatment.
source →This is an open label, single centre, phase II study of neoadjuvant drug treatment with dabrafenib + trametinib in patients with resectable American Joint Committee on Cancer (AJCC) Stage IIIB-C BRAF V600 mutation positive melanoma.
source →Background: * Pioglitazone is a drug that belongs to the class of antidiabetic agents called thiazolidinediones. It is approved for treatment of type 2 diabetes mellitus. * Research suggests that the thiazolidinediones may have anticancer activity that can reduce cancer risk or cause tumors to shrink.
source →This phase II trial is studying how well rosiglitazone works in preventing oral cancer in patients with oral leukoplakia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of rosiglitazone may keep cancer from forming in patients with oral leukoplakia
source →